SCHEMBL4150440

SCHEMBL4150440

COC(=O)c1ccc(C(C)NN)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
LMNA P02545 2/20 0.47
PPARG P37231 1/20 0.47
NCOA2 Q15596 1/20 0.47
NCOA1 Q15788 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
HPGD P15428 5/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
ATM Q13315 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
DAO P14920 1/20 0.40
MAPT P10636 5/20 0.38
KDM4E B2RXH2 5/20 0.38
ADRA2C P18825 1/20 0.36
MAOA P21397 1/20 0.36
ADRA1A P35348 1/20 0.36
DRD3 P35462 1/20 0.36
KCNH2 Q12809 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406988 0.83 NPSR1 (0.50) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL14448557 0.83 NPSR1 (0.50) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL2403566 0.82 NPSR1 (0.53) NPSR1LMNAPPARGNCOA2NCOA1
Hydrochloric Acid SCHEMBL2408434 0.81 NPSR1 (0.49) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL2654349 0.81 NPSR1 (0.51) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL3333257 0.81 NPSR1 (0.51) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL15061654 0.81 NPSR1 (0.45) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL27192566 0.79 NPSR1 (0.50) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL8254639 0.79 NPSR1 (0.50) NPSR1LMNAPPARGNCOA2NCOA1
SCHEMBL7454968 0.77 NPSR1 (0.51) NPSR1LMNAPPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440553-B1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE MERCK SHARP & DOHME (US) 2017-08-23 EP disclosed
US-8470773-B2 Thiophenes as glucagon receptor antagonists, compositions, and methods for their use MERCK SHARP & DOHME CORP. (US) 2013-06-25 US disclosed
US-20120108505-A1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE SCHERING CORPORATION 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108505-A1 THIOPHENES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE GLP1R, GCGR, GPR119 NPSR1 188/4885LMNA 4485/4885PPARG 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.